AFP and viral hepatitis: Viral hepatitis-related HCC has plateaued globally, whereas ALD and MASLD-related HCC incidence and mortality have increased,[17], [18], [19] highlighting a need to closely examine the utility of AFP-L3 and GALAD in the evolving high-risk population.